STOCK TITAN

[Form 4] Mersana Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Mersana Therapeutics (MRSN) insider activity: The SVP, Chief Development Officer reported RSU vesting of 250 shares of common stock on October 25, 2025, and an automatic sell-to-cover of 77 shares at $9.90 on October 27, 2025 under a Rule 10b5-1 trading plan adopted on May 10, 2023. Following these transactions, direct beneficial ownership is 2,922 shares.

The amounts reflect the one-for-twenty-five reverse stock split effected on July 25, 2025. Each RSU represented one common share, and the RSUs were fully vested as of October 25, 2025.

Attività insider di Mersana Therapeutics (MRSN): Il Senior Vice President e Chief Development Officer ha riportato la vesting di RSU pari a 250 azioni ordinarie il 25 ottobre 2025, e una vendita automatica per copertura di 77 azioni a 9,90$ il 27 ottobre 2025, nell'ambito di un piano di trading Rule 10b5-1 adottato il 10 maggio 2023. Dopo queste operazioni, la proprietà diretta è di 2.922 azioni.

Le cifre riflettono lo split azionario inverso di 1 contro 25 effettivo il 25 luglio 2025. Ogni RSU rappresentava una azione ordinaria, e le RSU erano completamente vestite al 25 ottobre 2025.

Actividad de insiders de Mersana Therapeutics (MRSN): El SVP y Director de Desarrollo reportó la vesting de RSU de 250 acciones comunes el 25 de octubre de 2025, y una venta automática para cubrir de 77 acciones a 9,90 dólares el 27 de octubre de 2025 bajo un plan de trading Rule 10b5-1 adoptado el 10 de mayo de 2023. Tras estas operaciones, la titularidad directa es de 2.922 acciones.

Las cantidades reflejan la división inversa de acciones de 1 por 25 llevada a cabo el 25 de julio de 2025. Cada RSU representaba una acción común, y las RSU estaban completamente vestidas al 25 de octubre de 2025.

Mersana Therapeutics (MRSN) 내부자 거래 활동: SVP 겸 최고 개발책임자가 2025년 10월 25일 일반주 250주에 대한 RSU의 vesting을 보고했고, 2025년 10월 27일 9.90달러로의 자동 매도-커버 77주를 Rule 10b5-1 트레이딩 계획 하에 시행했습니다. 이 거래 이후 직접 동일인 소유는 2,922주입니다.

금액은 2025년 7월 25일에 실행된 1 대 25의 역분할을 반영합니다. 각 RSU는 하나의 보통주를 나타내며 RSU는 2025년 10월 25일에 완전히 vest되었습니다.

Activité des initiés de Mersana Therapeutics (MRSN) : Le SVP, Directeur du développement, a rapporté la vesting de RSU de 250 actions ordinaires le 25 octobre 2025, et une vente automatique pour couverture de 77 actions à 9,90$ le 27 octobre 2025 dans le cadre d'un plan de trading Rule 10b5-1 adopté le 10 mai 2023. Suite à ces transactions, la propriété bénéficiaire directe est de 2 922 actions.

Les montants reflètent la scission inverse 1 pour 25 effectuée le 25 juillet 2025. Chaque RSU représentait une action ordinaire, et les RSU étaient entièrement acquises au 25 octobre 2025.

Insider-Tätigkeit von Mersana Therapeutics (MRSN): Der SVP, Chief Development Officer, meldete die Vesting von RSU in Höhe von 250 Stammaktien am 25. Oktober 2025, und einen automatischen Verkauf zur Absicherung von 77 Aktien zu 9,90 USD am 27. Oktober 2025 im Rahmen eines Rule 10b5-1-Handelsplans, der am 10. Mai 2023 angenommen wurde. Nach diesen Transaktionen beträgt die direkte beneficial ownership 2.922 Aktien.

Die Beträge spiegeln den am 25. Juli 2025 durchgeführten 1-zu-25-Reverse-Splits wider. Jede RSU stand für eine Stammaktie, und die RSUs waren am 25. Oktober 2025 vollständig vestet.

نشاط داخلي لشركة Mersana Therapeutics (MRSN): أبلغ نائب الرئيس الأول والمدير التنفيذي لتطوير العلاقات عن تخفيض RSU قدره 250 سهماً من الأسهم العادية في 25 أكتوبر 2025، وبيع تلقائي لتغطية 77 سهماً بسعر 9.90 دولار في 27 أكتوبر 2025 وفق خطة تداول Rule 10b5-1 المعتمدة في 10 مايو 2023. عقب هذه المعاملات، الملكية المباشرة هي 2,922 سهماً.

تعكس المبالغ تقسيم الأسهم العكسي بواقع واحد مقابل خمسة وعشرين الذي تم في 25 يوليو 2025. كل RSU يمثل سهماً عادياً واحداً، وكانت RSUs مكتملة الاستحقاق حتى 25 أكتوبر 2025.

Positive
  • None.
Negative
  • None.

Attività insider di Mersana Therapeutics (MRSN): Il Senior Vice President e Chief Development Officer ha riportato la vesting di RSU pari a 250 azioni ordinarie il 25 ottobre 2025, e una vendita automatica per copertura di 77 azioni a 9,90$ il 27 ottobre 2025, nell'ambito di un piano di trading Rule 10b5-1 adottato il 10 maggio 2023. Dopo queste operazioni, la proprietà diretta è di 2.922 azioni.

Le cifre riflettono lo split azionario inverso di 1 contro 25 effettivo il 25 luglio 2025. Ogni RSU rappresentava una azione ordinaria, e le RSU erano completamente vestite al 25 ottobre 2025.

Actividad de insiders de Mersana Therapeutics (MRSN): El SVP y Director de Desarrollo reportó la vesting de RSU de 250 acciones comunes el 25 de octubre de 2025, y una venta automática para cubrir de 77 acciones a 9,90 dólares el 27 de octubre de 2025 bajo un plan de trading Rule 10b5-1 adoptado el 10 de mayo de 2023. Tras estas operaciones, la titularidad directa es de 2.922 acciones.

Las cantidades reflejan la división inversa de acciones de 1 por 25 llevada a cabo el 25 de julio de 2025. Cada RSU representaba una acción común, y las RSU estaban completamente vestidas al 25 de octubre de 2025.

Mersana Therapeutics (MRSN) 내부자 거래 활동: SVP 겸 최고 개발책임자가 2025년 10월 25일 일반주 250주에 대한 RSU의 vesting을 보고했고, 2025년 10월 27일 9.90달러로의 자동 매도-커버 77주를 Rule 10b5-1 트레이딩 계획 하에 시행했습니다. 이 거래 이후 직접 동일인 소유는 2,922주입니다.

금액은 2025년 7월 25일에 실행된 1 대 25의 역분할을 반영합니다. 각 RSU는 하나의 보통주를 나타내며 RSU는 2025년 10월 25일에 완전히 vest되었습니다.

Activité des initiés de Mersana Therapeutics (MRSN) : Le SVP, Directeur du développement, a rapporté la vesting de RSU de 250 actions ordinaires le 25 octobre 2025, et une vente automatique pour couverture de 77 actions à 9,90$ le 27 octobre 2025 dans le cadre d'un plan de trading Rule 10b5-1 adopté le 10 mai 2023. Suite à ces transactions, la propriété bénéficiaire directe est de 2 922 actions.

Les montants reflètent la scission inverse 1 pour 25 effectuée le 25 juillet 2025. Chaque RSU représentait une action ordinaire, et les RSU étaient entièrement acquises au 25 octobre 2025.

Insider-Tätigkeit von Mersana Therapeutics (MRSN): Der SVP, Chief Development Officer, meldete die Vesting von RSU in Höhe von 250 Stammaktien am 25. Oktober 2025, und einen automatischen Verkauf zur Absicherung von 77 Aktien zu 9,90 USD am 27. Oktober 2025 im Rahmen eines Rule 10b5-1-Handelsplans, der am 10. Mai 2023 angenommen wurde. Nach diesen Transaktionen beträgt die direkte beneficial ownership 2.922 Aktien.

Die Beträge spiegeln den am 25. Juli 2025 durchgeführten 1-zu-25-Reverse-Splits wider. Jede RSU stand für eine Stammaktie, und die RSUs waren am 25. Oktober 2025 vollständig vestet.

نشاط داخلي لشركة Mersana Therapeutics (MRSN): أبلغ نائب الرئيس الأول والمدير التنفيذي لتطوير العلاقات عن تخفيض RSU قدره 250 سهماً من الأسهم العادية في 25 أكتوبر 2025، وبيع تلقائي لتغطية 77 سهماً بسعر 9.90 دولار في 27 أكتوبر 2025 وفق خطة تداول Rule 10b5-1 المعتمدة في 10 مايو 2023. عقب هذه المعاملات، الملكية المباشرة هي 2,922 سهماً.

تعكس المبالغ تقسيم الأسهم العكسي بواقع واحد مقابل خمسة وعشرين الذي تم في 25 يوليو 2025. كل RSU يمثل سهماً عادياً واحداً، وكانت RSUs مكتملة الاستحقاق حتى 25 أكتوبر 2025.

Mersana Therapeutics(MRSN)内幕交易活动:SVP兼首席开发官报告在2025年10月25日解锁250股普通股的RSU,并在2025年10月27日以每股9.90美元执行77股自动卖出以覆盖,依据于2023年5月10日通过的Rule 10b5-1交易计划。完成这些交易后,直接受益所有权为2,922股。

金额反映了在2025年7月25日实施的1比25的反向股票分割。每份RSU代表一股普通股,且RSU在2025年10月25日已全部归属。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bala Mohan

(Last) (First) (Middle)
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mersana Therapeutics, Inc. [ MRSN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Chief Development Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/25/2025 M(1) 250(2) A $0 2,999(2) D
Common Stock 10/27/2025 S(3) 77(2) D $9.9 2,922(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (4) 10/25/2025 M 250(2) (5) (5) Common Stock 250(2) $0 0(2) D
Explanation of Responses:
1. Represents shares of common stock received upon vesting of the restricted stock units ("RSUs") awarded to the Reporting Person on October 25, 2021.
2. Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.
3. Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
4. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
5. Fully vested as of October 25, 2025.
/s/ Alejandra Carvajal, Attorney-in-Fact 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MRSN report on Form 4?

The SVP, Chief Development Officer reported RSU vesting of 250 shares and an automatic sell-to-cover of 77 shares.

How many MRSN shares vested from RSUs and when?

250 shares vested on October 25, 2025; each RSU equaled one common share.

How many MRSN shares were sold to cover taxes and at what price?

77 shares were sold at $9.90 on October 27, 2025 to satisfy tax withholding.

Is the MRSN sale covered by a Rule 10b5-1 plan?

Yes. The sale was pursuant to a Rule 10b5-1 plan adopted on May 10, 2023 and executed as an automatic sell-to-cover.

What is the MRSN insider’s beneficial ownership after the transactions?

Direct beneficial ownership is 2,922 shares following the reported transactions.

Why do the MRSN share counts look adjusted?

Figures reflect the one-for-twenty-five reverse stock split effected on July 25, 2025.
Mersana Therapeutics Inc

NASDAQ:MRSN

MRSN Rankings

MRSN Latest News

MRSN Latest SEC Filings

MRSN Stock Data

52.85M
4.91M
1.46%
62.48%
8.68%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE